SCRS Welcomes TD2 as Global Impact and Oncology Spirit Partner

April 04, 2024

April 4, 2024 – The Society for Clinical Research Sites (SCRS) is pleased to welcome Translational Drug Development (TD2) as an SCRS Global Impact Partner and Oncology Spirit Partner. TD2 is a leading provider of comprehensive preclinical drug development, translational and clinical trial services based in Scottsdale, Arizona.

SCRS Global Impact Partners (GIPs) are comprised of industry sponsors, CROs, service providers, and site networks that are dedicated to supporting SCRS’ mission of ensuring site sustainability. GIP representatives participate in the development of SCRS events, advocacy initiatives, and educational content for research sites.

With TD2’s involvement as an Oncology Spirit Partner, the organization will contribute to the SCRS Oncology Program, creating site-focused resources for oncology research success. TD2 will also exhibit at the SCRS Oncology Site Solutions Summit on April 10-11, 2024, in Atlanta, Georgia. The Oncology Site Solutions Summit brings together research sites, sponsors, CROs, and solution providers to learn and share solutions for more efficient oncology research operations.

“We are thrilled to partner with SCRS in their important mission advocating for sites,” said Susan Night, Vice President of Site Engagement and Network Strategy for TD2. “It aligns perfectly with TD2’s commitment to building purposeful partnerships aimed at advancing science through clinical research with the goal of improving access to novel therapeutics and outcomes for patients.”

“Collaboration is a key ingredient to the future of precision medicine,” shared Sean Soth, SVP of Strategy and Global Business Partnerships for SCRS. “TD2 brings a unique approach and suite of services into our GIP community as a CRO focused on precision oncology. In many ways, our network can learn alongside TD2 about opportunities for sites and industry to collaborate,” continued Soth. “SCRS Global Impact Partners are committed to addressing challenges faced by research sites today. As a leading precision oncology CRO, TD2 brings unparalleled expertise and resources to advance clinical research and drug development in the oncology space. By aligning our efforts, we can make substantial strides in ensuring sustainable cancer research and improving patient outcomes.”

For more information about the SCRS GIP program, visit

Top Trends in ADC Drug Development

Antibody drug conjugates (ADCs) represent a significant advancement in cancer therapy, combining monoclonal antibodies with potent chemotherapeutic ...

Read more +

Unlocking Insights: Top 5 Reasons to Incorporate Orthotopic GBM PDX Models into Your Preclinical Evaluation

In the landscape of glioblastoma multiforme (GBM) research, the utilization of Orthotopic GBM Patient-Derived Xenograft (PDX) models stands as a ...

Read more +

The Vital Role of Highly Characterized Glioblastoma PDX Models in Preclinical Cancer Research: Insights from TD2's Most Recent Studies

The fight against Glioblastoma multiforme (GBM), one of the most aggressive forms of brain cancer, hinges on the development and use of advanced ...

Read more +

Get Started

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.